Citadel Advisors’s Aerie Pharmaceuticals AERI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-228,542
| Closed | -$3.46M | – | 15970 |
|
|
2022
Q3 | $3.46M | Buy |
228,542
+136,585
| +149% | +$1.59M | ﹤0.01% | 4522 |
|
|
2022
Q2 | $690K | Sell |
91,957
-775
| -0.8% | -$5.46K | ﹤0.01% | 7906 |
|
|
2022
Q1 | $844K | Buy |
92,732
+57,551
| +164% | +$444K | ﹤0.01% | 8102 |
|
|
2021
Q4 | $247K | Sell |
35,181
-620,400
| -95% | -$6.49M | ﹤0.01% | 11403 |
|
|
2021
Q3 | $7.47M | Buy |
655,581
+594,846
| +979% | +$8.7M | ﹤0.01% | 3570 |
|
|
2021
Q2 | $972K | Sell |
60,735
-27,105
| -31% | -$465K | ﹤0.01% | 8439 |
|
|
2021
Q1 | $1.57M | Sell |
87,840
-264,315
| -75% | -$4.57M | ﹤0.01% | 6994 |
|
|
2020
Q4 | $4.76M | Sell |
352,155
-498,875
| -59% | -$6.03M | ﹤0.01% | 3782 |
|
|
2020
Q3 | $10M | Sell |
851,030
-856,145
| -50% | -$10.4M | ﹤0.01% | 2296 |
|
|
2020
Q2 | $25.2M | Buy |
1,707,175
+1,344,538
| +371% | +$19.9M | 0.01% | 1299 |
|
|
2020
Q1 | $4.89M | Sell |
362,637
-469,955
| -56% | -$8.92M | ﹤0.01% | 2734 |
|
|
2019
Q4 | $20.1M | Buy |
832,592
+541,221
| +186% | +$11.2M | 0.01% | 1471 |
|
|
2019
Q3 | $5.6M | Buy |
291,371
+164,870
| +130% | +$3.78M | ﹤0.01% | 2954 |
|
|
2019
Q2 | $3.74M | Sell |
126,501
-235,359
| -65% | -$9.07M | ﹤0.01% | 3513 |
|
|
2019
Q1 | $17.2M | Sell |
361,860
-1,176,270
| -76% | -$51.8M | 0.01% | 1483 |
|
|
2018
Q4 | $55.5M | Buy |
1,538,130
+147,501
| +11% | +$6.92M | 0.03% | 564 |
|
|
2018
Q3 | $85.6M | Buy |
1,390,629
+1,381,525
| +15,175% | +$88.8M | 0.04% | 475 |
|
|
2018
Q2 | $615K | Sell |
9,104
-2,057
| -18% | -$115K | ﹤0.01% | 6036 |
|
|
2018
Q1 | $606K | Sell |
11,161
-23,742
| -68% | -$1.33M | ﹤0.01% | 5573 |
|
|
2017
Q4 | $2.08M | Sell |
34,903
-169,418
| -83% | -$10.3M | ﹤0.01% | 3579 |
|
|
2017
Q3 | $9.93M | Buy |
204,321
+109,462
| +115% | +$5.97M | 0.01% | 1611 |
|
|
2017
Q2 | $4.99M | Sell |
94,859
-327,430
| -78% | -$15.2M | ﹤0.01% | 2134 |
|
|
2017
Q1 | $19.2M | Sell |
422,289
-688,306
| -62% | -$30.7M | 0.02% | 986 |
|
|
2016
Q4 | $42M | Buy |
1,110,595
+551,541
| +99% | +$20.9M | 0.04% | 453 |
|
|
2016
Q3 | $21.1M | Buy |
+559,054
| New | +$12.3M | 0.02% | 842 |
|
|
2016
Q2 | – | Sell |
-12,917
| Closed | -$209K | – | 7583 |
|
|
2016
Q1 | $157K | Buy |
+12,917
| New | +$204K | ﹤0.01% | 5801 |
|
|
2015
Q4 | – | Sell |
-12,403
| Closed | -$289K | – | 9363 |
|
|
2015
Q3 | $220K | Buy |
12,403
+7,552
| +156% | +$137K | ﹤0.01% | 6018 |
|
|
2015
Q2 | $86K | Buy |
+4,851
| New | +$88.9K | ﹤0.01% | 7239 |
|
Citadel Advisors's AERI Position: Q4 2022 in Review
Citadel Advisors sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 228,542 shares — an estimated $3.46M sold.
Citadel Advisors first reported a position in AERI in Q2 2015 and held it in 28 quarters. The position peaked at $85.6M in Q3 2018. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.
- Citadel Advisors reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
- Citadel Advisors sold 228,542 Aerie Pharmaceuticals shares in Q4 2022, an estimated $3.46M.
- Citadel Advisors first reported a position in Aerie Pharmaceuticals in Q2 2015 and held it in 28 quarters.
- Citadel Advisors's Aerie Pharmaceuticals position peaked at $85.6M in Q3 2018.
- 0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.
Based on Citadel Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.